Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 13 of 14.
Sep 2010
Aug 2010
24 Aug · Business
Board of Directors in its Meeting held on August 24, 2010 has inter alia approved issue of Fully Convertible warrants on a preferential basis to Sunev Pharma Solutions Ltd. a promoter group company upto 5% of the total capital in accordance with SEBI ( Substantial Acquisitions and Takeovers) Regulations, 1997. The same is also subject to applicable provisions of SEBI/Companies Act and approval of shareholders at the forthcoming Annual General Meeting.16 Aug · Board meeting
To inter alia consider and approve issue of fully convertible warrants to promoters/persons acting in concert on a preferential basis subject to approval of the general meeting.
Jul 2010
31 Jul · Meeting
Register of Members and Share Transfer Books shall remain closed from September 25, 2010 to September 30, 2010 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend. The Annual General Meeting of the Company will be held on September 27, 2010.31 Jul · Dividend
Board of Directors of the Company at its meeting held on July 31, 2010, recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2010 subject to approval of the same by shareholders at the Annual General Meeting.21 Jul · Board meeting
To inter alia consider and approve : (1) Unaudited Financial Results (Provisional) for the quarter ended June 30, 2010; (2) Annual Accounts of the Company for the year ended March 31, 2010; (3) Recommendation of dividend for the year 2009-2010; (4) Fix the Date of Annual General Meeting; (5) Any other business with the permission of the Chair.
Jun 2010
10 Jun · FCCBs
Company and the bondholders had arrived at a Settlement Agreement dated March 3, 2010 with the FCCB holders for settlement of FCCBs of USD 12m. The Settlement was arrived at USD 14m (including interest component) against a cash payment of USD 9m and rollover of USD 5m of FCCBs for a period of 5 years, until February 15, 2015. In accordance with the said Agreement, the Company has made full and final payment of USD 9m and also received approval of Reserve Bank of India for rollover of FCCBs of USD 5m. With this, the entire issue of FCCB has been fully and finally settled with the FCCB holders.
May 2010
22 May · FCCBs
Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn with YTM @ 4% with maturity till February 15, 2015.
Apr 2010
24 Apr · Board meeting
Outcome of Board Meeting held on April 24, 2010. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Apr · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended March 31, 2010 and to consider allotment of shares under Employees Stock Options Scheme.9 Apr · Updates
Vide its letter dated April 09, 2010 tha " Venus Remedies receives GMP Certification from Botswana." The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
15 Mar · Updates
"SULBACTOMAX a Ceftriaxone Sulbactam combination patent granted to Venus in India." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Mar · Updates
The Company and its FCCB holders have arrived at an amicable settlement agreement pertaining to the redemption of the $12-million foreign currency convertible bond (FCCB) issue. Pursuant to directions of the Hon'ble Punjab and Haryana High Court in Chandigarh, both the parties have reached settlement . As per the agreement between the parties, the Company will pay a part of the outstanding FCCBs and USD five million remaining shall be rolled over for a period of 5 years, wherein the international investors will remain invested in the Company. The rollover is subject to applicable statutory approvals. The price of the rollover will be as per the SEBI floor price as applicable when FCCBs were originally issued. In accordance with the terms of the settlement agreement, the FCCB holders will withdraw the winding up petition, which is yet to be admitted against the Company, as per the milestones agreed and parties will file a joint application in the court to that effect
Feb 2010
22 Feb · Updates
Venus Remedies' German arm gets approval to market carbapenem injection in Portugal. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Feb · Updates
Venus Remedies Ltd has received yet another Good Manufacturing Practices (GMP) approval from Ethiopia's Drug Administration and Control Authority (DACA) for four of its facilities viz. Oncology liquid, Oncology Lyophilized, Dry powder Cephalosporin and Dry powder Carbapenem. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
28 Jan · Updates
"Venus Remedies launches India's First Infusion FDC antibiotic to fight GI infections." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jan · Board meeting
Interalia to consider and approve Unaudited Financial Results (Provisional) for the quarter ended December 31, 2009.
Nov 2009
12 Nov · Updates
Following: "Venus Bags another Product Patent from South Africa for POTENTOX". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
31 Oct · Board meeting
Board of Directors at its meeting held on October 31, 2009 have unanimously elected Mr. Pawan Chaudhary the Managing Director as the Chairman of the Board of Directors.21 Oct · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended September 30, 2009.
Sep 2009
30 Sep · Meeting
Outcome of Annual General Meeting of the Company held on September 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Sep · Updates
Following: "Venus Outlicensed "SULBACTOMAX" to South Korea". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Sep · Meeting
Notice of the Annual General Meeting of the Members of the company to be held on September 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Sep · Updates
Following: "First Indian Product Patent Granted to Venus Remedies for Potentox". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Sep · Updates
Following: "DCGI Permission for Manufacturing and Marketing of New Infusion "MEBATIC" ". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
26 Aug · Meeting
Board of Directors of the Company at its meeting held on August 21, 2009 : 1) Fixed the date of Annual General Meeting as September 30, 2009. 2) The Board also decided that Register of Members and Share Transfer Books shall remain closed from September 20, 2009 to September 30, 2009 (both days inclusive) for the purpose of Annual General Meeting and for the purpose of determining of entitlement to dividend.25 Aug · Dividend
Board of Directors at its meeting held on August 21, 2009 recommended a dividend @ of 30% i.e. Rs.3/- per share for the financial year ended March 31, 2009 subject to approval of the same by shareholders at the Annual General Meeting.25 Aug · Management
Board of Directors at its meeting held on August 21, 2009, have accepted resignation of Dr. Anil Gulati as a Non-Executive Director w.e.f. August 17, 2009.11 Aug · Board meeting
To inter alia consider and approve : (1) Annual Accounts of the Company for the year ended March 31, 2009, (2) Recommendation of dividend for the year 2008-2009, (3) Fix the Date of Annual General Meeting, (4) Any other business with the permission of the Chair.4 Aug · Updates
Venus Remedies Limited had informed the Exchange vide its letter dated August 04, 2009, regarding the following: "Product Patent for "TOBRACEF" granted in South Africa". The Company has now informed the Exchange that the validity period of the Patent should be read as May 2026 as mentioned in last paragraph. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Aug · Updates
"Venus Remedies Limited, one of the leading research based companies in India has added another Product Patent for TOBRACEF in its strong IPR basket. The Companies and Intellectual Property Registration Office (CIPRO), South Africa, granted the patent of TOBRACEF which is indicated for the treatment of complicated mixed bacterial infection of Acute Pulmonary Exacerbations / Cystic Fibrosis / Chronic Obstructive Pulmonary Disease. The product is a novel fixed dose combination of cephalosporin and aminoglycoside". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
25 Jul · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended June 30, 2009.
Jun 2009
16 Jun · Updates
Vide its letter dated June 16, 2009 regarding "Another Product Patent Granted to Venus Remedies in South Africa". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jun · Change in registered office
Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. Now the Current address is: SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101.1 Jun · Updates
Korean Intellectual Property Office (KIPO) has granted a Product Patent to one of the research products of Venus used for the treatment of pneumonia. This unique combination of a Cephalosporin with Aminoglycoside is a super specialty product resulted from the team efforts of Venus Medicine Research Centre and its patent was filed in 2004.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
18 May · Updates
"DCGI Permission to Conduct Phase-III Clinical Trial of a Novel Aminoglycoside Formulation". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 May · Management
Ms. Nidhi Singla, Company Secretary has been appointed as Compliance Officer w.e.f. May 01, 2009 as Ms. Amarjeet Kaur, Company Secretary has resigned from the Company5 May · Allotment of Equity Shares
Board of Directors at its meeting held on April 30, 2009 have approved allotment of 19,868 equity shares of Rs.10/- each cash at par under Employees Stock Options Scheme pursuant to exercise of options.5 May · Updates
Venus Remedies Limited, has received its first permission to conduct Phase 1 Clinical trials for its Investigational New Drug application of VRP 1620 from Drugs Controller General of India. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
21 Apr · Board meeting
To consider interalia Unaudited Financial Results (Provisional) for the quarter ended March 31, 2009 and to consider allotment of shares under Employees Stock Options Scheme.
Jan 2009
21 Jan · Updates
"The Company's manufacturing facilities at Baddi Campus have been accredited with Good Manufacturing Practices certificate by the Ministry of Health and Medical Education of Iran which will enable the Company to export its product to Iranian market". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Board meeting
Meeting on 31 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
17 Oct · Meeting
At the Annual General Meeting of the members of the Company held on September 22, 2008 the following business were transacted unanimously as under : 1) Adoption of Balance Sheet as on March 31, 2008 and Profit & Loss Account for the year ended on that date; 2) Re-appointment of Dr. Anil Gulati, Dr. S.K. Chadha and Mr. Hari Pal Verma as directors of the Company; 3) Declaration of Dividend at the rate of 40% on paid up equity share capital of the Company for the year ended March 31, 2008; 4) Increase in remuneration of Mr. Pawan Chaudhary, Managing Director, Ms. Manu Chaudhary Deputy Managing Director, Mr. Peeyush Jain Executive Director and Mr. Ashutosh Jain Executive Director of the Company. 5) Modification of Employees Stock Option Scheme 2005 to the extent that Fringe Benefit Tax as applicable on ESOPs shall be recoverable by the Employer from the employees to the extent such Fringe Benefit Tax is payable by the Employer on the stock options as per the provisions of Income Tax Act.14 Oct · Board meeting
Meeting on 30 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”